surmount-1 tirzepatide weight loss percent 72 weeks Adults with obesity using maintain 'remarkable' at 88 surmount-1 tirzepatide trial obesity without

Adrian, a systems engineer, had a choice between paying out of pocket for a GLP-1 medication or feeding his family

Side Effects and Safety Profile Common Side Effects Gastrointestinal effects are the most frequently reported adverse events in clinical trials: Nausea (reported by 1233% of participants depending on dose) Diarrhea (1223%) Constipation (611%) Vomiting (59%) Decreased appetite (considered both a therapeutic effect and side effect) Abdominal pain (58%) Dyspepsia/heartburn (58%) These effects are most common during dose escalation and typically improve within 24 weeks at each new dose level

The studies assessed the SOD, CAT, GPx, GSH, and MDA levels in different experimental clinical situations in rats to investigate whether the oxidative reaction increased or decreased

Maintaining adequate protein intake, micronutrients, and a measured weight loss pace can reduce your risk